Dossier
Pharma sector
Coverage of Pharma sector in the Nexus archive.
- Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most
The article discusses concerns that the U.S.-China biotech crackdown could harm American scientists, as China's biotech sector grows, contributing 34% of global new drugs in clinical development and out-licensing deals reaching $137.7 billion by 2025. It highlights tensions over intellectual property fears and state-run companies in China.
- European producers press Brussels to shut Russian aluminium loophole
European producers are urging Brussels to close a loophole related to Russian aluminium. The pharmaceutical sector is also pushing the EU to address a funding gap in life sciences.